# Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema

> **NCT01363440** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 466 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
- **PROCEDURE:** Macular Laser Photocoagulation

## Key facts

- **NCT ID:** NCT01363440
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-01
- **Final completion:** 2014-11
- **Target enrollment:** 466 (ACTUAL)
- **Last updated:** 2016-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01363440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01363440, "Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01363440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*